PepGen, Inc. (NASDAQ:PEPG – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $11.40.
PEPG has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Weiss Ratings raised shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Finally, Wall Street Zen cut shares of PepGen from a “hold” rating to a “sell” rating in a report on Saturday, October 10th.
Read Our Latest Stock Report on PEPG
PepGen Stock Down 5.3%
PepGen stock opened at $2.32 on Friday. The firm has a market cap of $160.68 million, a P/E ratio of -1.77 and a beta of 2.02. The business has a fifty day moving average of $2.69 and a two-hundred day moving average of $3.01. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80.
PepGen (NASDAQ:PEPG – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. Equities analysts expect that PepGen will post -1.11 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rangeley Capital LLC raised its holdings in shares of PepGen by 88.1% during the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock worth $121,000 after purchasing an additional 31,896 shares during the last quarter. Group One Trading LLC purchased a new stake in PepGen in the first quarter valued at $77,000. Seven Fleet Capital Management LP purchased a new stake in PepGen in the first quarter valued at $105,000. Dimensional Fund Advisors LP boosted its holdings in PepGen by 60.4% in the first quarter. Dimensional Fund Advisors LP now owns 216,824 shares of the company’s stock valued at $394,000 after purchasing an additional 81,608 shares during the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in PepGen during the 2nd quarter worth about $171,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.
PepGen Company Profile
PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.
PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.
Featured Stories
- Five stocks we like better than PepGen
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.
